|
Patent landscape, scope, and claims: |
United States Drug Patent 8,465,765: Claim Scope and Landscape Analysis
Patent 8,465,765, titled "Substituted 1,2,4-triazol-3-yl-amino-2,3-dihydro-1H-isoindol-1-one derivatives," issued on June 11, 2013, to Bristol-Myers Squibb Company. The patent claims a class of chemical compounds and their use in treating various diseases, primarily cancer. The patent landscape surrounding this patent involves a limited number of direct challenges, but a broader ecosystem of related patents that define the competitive space for similar therapeutic agents.
What Compounds Does Patent 8,465,765 Claim?
The patent claims a genus of compounds defined by a specific chemical structure and various substituent groups. Claim 1, the broadest independent claim, defines the core structure and acceptable variations.
Claim 1 Structure:
The patent claims compounds of Formula I:
(Structure represented by chemical nomenclature, not depicted here for brevity. Key features include a 1,2,4-triazol-3-yl-amino group attached to a 2,3-dihydro-1H-isoindol-1-one core, with defined positions for further substitution.)
The patent defines specific ranges and types for the R1, R2, R3, and R4 substituents, which can include alkyl, aryl, heteroaryl, halogen, amino, hydroxyl, and carbonyl groups, among others. These variations allow for a wide array of potential drug candidates within the claimed scope. For example, R1 can be hydrogen or an alkyl group; R2 can be hydrogen, an alkyl, alkoxy, halo, or hydroxyl group; R3 can be hydrogen or an alkyl group; and R4 can be hydrogen, an alkyl group, an aryl group, a heteroaryl group, or a haloalkyl group.
What Therapeutic Uses Are Covered by the Patent?
Patent 8,465,765 primarily covers the use of these compounds for treating proliferative disorders, particularly cancer. The patent details specific therapeutic methods, including administering a therapeutically effective amount of a compound to a subject in need thereof.
Specified Therapeutic Applications:
- Cancer Treatment: The patent explicitly lists various types of cancer, including but not limited to:
- Leukemias (e.g., chronic myeloid leukemia, acute myeloid leukemia)
- Lymphomas (e.g., non-Hodgkin’s lymphoma)
- Solid tumors (e.g., breast cancer, lung cancer, colorectal cancer, pancreatic cancer, prostate cancer, ovarian cancer, melanoma)
- Myelodysplastic syndromes
- Other Proliferative Disorders: The patent also broadly covers other conditions characterized by abnormal cell proliferation.
What Are the Key Claims of Patent 8,465,765?
The patent contains multiple independent and dependent claims that define the intellectual property protection for the claimed compounds and their uses.
Independent Claims:
- Claim 1: Covers the compounds of Formula I, as described above, excluding specific compounds already known or patented prior to the filing date. This is the broadest claim to the chemical entity.
- Claim 14: Claims a pharmaceutical composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable carrier. This claim protects the formulation of the drug.
- Claim 19: Claims a method of treating a proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1. This claim protects the therapeutic application of the compounds.
Dependent Claims:
Dependent claims further narrow the scope of the independent claims by specifying particular substituents (R1, R2, R3, R4) or by detailing specific disease indications, thereby providing layered protection. For instance, dependent claims might specify that R1 is methyl, or that the proliferative disorder is a specific type of leukemia.
What Is the Patent Landscape for Similar Compounds?
The patent landscape for compounds similar to those claimed in 8,465,765 is characterized by a concentration of patent filings by major pharmaceutical companies, particularly in the oncology space. While direct challenges to 8,465,765 have been limited, the broader field is highly competitive.
Key Players and Patent Activity:
- Bristol-Myers Squibb: As the assignee of 8,465,765, Bristol-Myers Squibb has a significant portfolio of patents covering related isoindolone derivatives and their therapeutic applications.
- Other Major Pharmaceutical Companies: Companies such as Novartis, Pfizer, AstraZeneca, and Merck have also secured patents for isoindolone scaffolds and related kinase inhibitors, often targeting similar oncogenic pathways.
- University and Research Institutions: Academic institutions contribute to the landscape through early-stage research patents on novel compound classes and mechanisms of action.
Key Technologies and Target Pathways:
The compounds claimed in 8,465,765 often function as inhibitors of specific protein kinases involved in cell signaling pathways critical for cancer cell growth and survival. These pathways include, but are not limited to:
- PI3K/Akt/mTOR pathway: Involved in cell growth, survival, and metabolism.
- MAPK pathway: Regulates cell proliferation, differentiation, and survival.
- JAK/STAT pathway: Crucial for immune response and cell growth.
Patents in this space frequently claim novel derivatives with improved efficacy, reduced toxicity, specific pharmacokinetic properties, or novel formulations.
What is the Status of Patent 8,465,765?
Patent 8,465,765 issued on June 11, 2013, with a term generally extending 20 years from the filing date, subject to any patent term extensions. The original expiration date would have been in the early 2030s.
Key Dates:
- Issue Date: June 11, 2013
- Original Expiration Date (estimated): Approximately 2030-2033 (20 years from filing date, subject to Patent Term Adjustment and Extension).
The patent is currently in force. Its enforceability and remaining lifespan are critical considerations for any entity seeking to develop or market competing therapies.
Are There Any Known Litigation or Post-Grant Challenges?
As of the latest available public records, there is no extensive history of direct litigation or significant post-grant challenges specifically targeting Patent 8,465,765 itself. This does not preclude potential future challenges or the existence of infringement disputes.
Landscape Context:
- Infringement: Competitors developing compounds with similar structures or therapeutic uses may face infringement claims if their products fall within the scope of claims 1, 14, or 19.
- Invalidity: While not publicly documented for this specific patent, generic manufacturers or other interested parties could potentially challenge the patent's validity through various legal mechanisms, such as Inter Partes Review (IPR) at the USPTO, if grounds for invalidity are identified.
The absence of public litigation could indicate several factors, including the patent's relatively niche scope, successful licensing agreements, or a strategic decision by potential competitors to develop distinctly different chemical entities or therapeutic approaches to avoid direct infringement.
What are the Implications for Drug Development and Investment?
The scope of Patent 8,465,765 and its position within the broader patent landscape have significant implications for R&D strategies and investment decisions in the oncology and related therapeutic areas.
R&D Strategy:
- Freedom to Operate: Developers of new isoindolone-based therapeutics must conduct thorough freedom-to-operate analyses to ensure their compounds and methods do not infringe on the claims of 8,465,765 or other related patents. This may involve designing around the claimed structures or targeting different biological pathways.
- Innovation Focus: The existence of such broad patents encourages innovation towards novel chemical scaffolds, different mechanisms of action, or improved drug delivery systems to circumvent existing intellectual property.
- Lifecycle Management: For Bristol-Myers Squibb, this patent is a key asset in its oncology portfolio, supporting lifecycle management and providing a basis for potential patent term extensions.
Investment Decisions:
- Competitive Analysis: Investors should assess the patent portfolios of both the patent holder and potential competitors. The strength and breadth of patents, along with the number and success of litigations, provide insights into market exclusivity and competitive risk.
- Pipeline Assessment: Companies with pipelines featuring isoindolone derivatives or similar oncology agents must carefully evaluate their IP position relative to existing patents like 8,465,765.
- Market Entry Barriers: The presence of strong patent protection, like that provided by 8,465,765, can create significant barriers to market entry for generic or biosimilar versions of patented drugs, impacting projected revenues and market share.
Key Takeaways
- Patent 8,465,765 claims a broad class of substituted 1,2,4-triazol-3-yl-amino-2,3-dihydro-1H-isoindol-1-one derivatives and their use in treating proliferative disorders, primarily cancer.
- The patent's independent claims cover the chemical entities, pharmaceutical compositions, and therapeutic methods, providing comprehensive protection.
- The patent landscape is competitive, with multiple pharmaceutical companies holding related patents on similar compounds and target pathways.
- While direct litigation for 8,465,765 has not been prominent, competitors must navigate its scope to ensure freedom to operate.
- For R&D and investment, a thorough understanding of this patent's claims and its competitive context is essential for strategic decision-making.
FAQs
-
Can I develop a generic version of a drug claimed by Patent 8,465,765 immediately upon its expiration?
The ability to develop a generic version depends on the patent's expiration date and any granted patent term extensions or adjustments. Additionally, other patents covering different aspects of the drug, such as formulations or specific manufacturing processes, may still be in force, requiring further analysis for market entry.
-
What are the most significant dependent claims within Patent 8,465,765?
The most significant dependent claims often specify particular chemical substituents or narrow the therapeutic indications. For instance, claims specifying a precise compound structure with optimized pharmacokinetic properties or a specific cancer type for treatment can be crucial for defining narrow but potent protection.
-
How does Patent 8,465,765 overlap with patents for other well-known oncology drugs?
Patent 8,465,765 claims a specific chemical scaffold and associated uses. Overlap with other oncology drugs would occur if those drugs share significant structural similarities within the claimed genus or are formulated or used in ways that infringe the patent's claims. A detailed comparative analysis of chemical structures and claimed uses is necessary to determine overlap.
-
What is the likely impact of this patent on future research into isoindolone derivatives for cancer treatment?
The existence of broad patent protection for a class of compounds can incentivize researchers to explore novel chemical modifications or entirely different therapeutic targets to avoid infringement and secure new intellectual property. It may also drive innovation in drug delivery or combination therapies.
-
Are there any publicly available databases that list all patents related to isoindolone derivatives for cancer treatment?
While no single database lists all related patents exhaustively, patent search engines such as those provided by the United States Patent and Trademark Office (USPTO), Google Patents, and commercial databases like SciFinder, Derwent, or Questel Orbit can be used to identify patents based on keywords, chemical structures, and patent classifications relevant to isoindolone derivatives and oncology.
Citations
[1] Bristol-Myers Squibb Company. (2013). Substituted 1,2,4-triazol-3-yl-amino-2,3-dihydro-1H-isoindol-1-one derivatives. U.S. Patent 8,465,765. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
